Published in J Immunol on March 01, 1970
A tumor antigen in tissue cultures derived from patients with Hodgkin's disease. Proc Natl Acad Sci U S A (1973) 1.09
Lambda-chain production in human lymphoblast-mouse fibroblast hybrids. Proc Natl Acad Sci U S A (1973) 1.06
The interaction of normal lymphocytes and cells from lymphoid cell lines. IV. HL-A typing of the cell line cells. Immunology (1973) 0.97
Chemical markers of transplantation individuality solubilized with sonic energy. Bacteriol Rev (1971) 0.89
Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell (1994) 9.51
Membrane properties of living mammalian cells as studied by enzymatic hydrolysis of fluorogenic esters. Proc Natl Acad Sci U S A (1966) 8.92
A procedure for rapid and sensitive staining of protein fractionated by polyacrylamide gel electrophoresis. Anal Biochem (1967) 7.96
Generation of protein-reactive antibodies by short peptides is an event of high frequency: implications for the structural basis of immune recognition. Proc Natl Acad Sci U S A (1983) 4.56
Protein iodination with solid state lactoperoxidase. Biochemistry (1974) 4.52
Electrophoretic heterogeneity of polypeptide chains of specific antibodies. Science (1966) 3.88
Focal antibody production by transferred spleen cells in irradiated mice. Science (1965) 3.12
Enhancement of sheep red blood cell human lymphocyte rosette formation by the sulfhydryl compound 2-amino ethylisothiouronium bromide. Clin Immunol Immunopathol (1975) 3.11
Human colonic adenocarcinoma cells. I. Establishment and description of a new line. In Vitro (1976) 2.65
Transplantation antigens: introductory symposium. Mixed leukocyte cultures and HL-A antigens. I. Reactivity of young fetuses, newborns and mothers at delivery. Transplant Proc (1971) 2.63
The impact of comorbid and sociodemographic factors on access to renal transplantation. JAMA (1993) 2.54
Integrin alpha v beta 3 rescues melanoma cells from apoptosis in three-dimensional dermal collagen. Proc Natl Acad Sci U S A (1994) 2.30
Unique glycoprotein-proteoglycan complex defined by monoclonal antibody on human melanoma cells. Proc Natl Acad Sci U S A (1982) 2.21
Salt extraction of soluble HL-A antigens. Science (1971) 2.18
Separation of 7S gamma-1-globulin, 7S gamma-2-globulin and macroglobulin guinea pig antibodies. Proc Soc Exp Biol Med (1966) 2.08
Expression of tissue factor by melanoma cells promotes efficient hematogenous metastasis. Proc Natl Acad Sci U S A (1992) 2.07
Detection of ganglioside GD2 in tumor tissues and sera of neuroblastoma patients. Cancer Res (1984) 2.01
Serologic evidence for antigens controlled by the Ir region in mice. J Exp Med (1973) 1.94
Individualization of cyclosporine therapy using pharmacokinetic and pharmacodynamic parameters. Transplantation (1985) 1.83
Structural studies of murine I-E and human DR antigens. Mol Immunol (1979) 1.79
Transplantation antigens. Adv Immunol (1970) 1.70
Murine Ia and human DR antigens: homology of amino-terminal sequences. Proc Natl Acad Sci U S A (1978) 1.70
Augmentation of antibody dependent cell mediated cytotoxicity following in vivo therapy with recombinant interleukin 2. Cancer Res (1990) 1.69
Downregulation of transcription factor SOX2 in cancer stem cells suppresses growth and metastasis of lung cancer. Br J Cancer (2011) 1.69
Disialoganglioside GD2 on human neuroblastoma cells: target antigen for monoclonal antibody-mediated cytolysis and suppression of tumor growth. Cancer Res (1987) 1.68
Phase I trial of a human-mouse chimeric anti-disialoganglioside monoclonal antibody ch14.18 in patients with refractory neuroblastoma and osteosarcoma. J Clin Oncol (1998) 1.67
Targeted interleukin-2 therapy for spontaneous neuroblastoma metastases to bone marrow. J Natl Cancer Inst (1997) 1.64
Natural killer cell-mediated eradication of neuroblastoma metastases to bone marrow by targeted interleukin-2 therapy. Blood (1998) 1.64
A phase I/IB trial of murine monoclonal anti-GD2 antibody 14.G2a plus interleukin-2 in children with refractory neuroblastoma: a report of the Children's Cancer Group. Cancer (1997) 1.63
A phase I study of human/mouse chimeric antiganglioside GD2 antibody ch14.18 in patients with neuroblastoma. Eur J Cancer (1995) 1.59
A rapid method for direct HL-A typing of cultured lymphoid cells. J Immunol (1971) 1.55
Antibody-targeted interleukin 2 stimulates T-cell killing of autologous tumor cells. Proc Natl Acad Sci U S A (1992) 1.51
En bloc transplantation of kidneys from pediatric donors. J Urol (1996) 1.51
Characterization of Ia antigens in mouse serum. J Immunol (1976) 1.51
Human neural cell adhesion molecule L1 and rat homologue NILE are ligands for integrin alpha v beta 3. J Cell Biol (1996) 1.50
Effect of a chimeric anti-ganglioside GD2 antibody on cell-mediated lysis of human neuroblastoma cells. Cancer Res (1991) 1.48
Antigens associated with a human lung adenocarcinoma defined by monoclonal antibodies. Cancer Res (1984) 1.48
The synergistic effects of cyclosporine and sirolimus. Transplantation (1997) 1.47
Functional properties and effect on growth suppression of human neuroblastoma tumors by isotype switch variants of monoclonal antiganglioside GD2 antibody 14.18. Cancer Res (1989) 1.45
An Arg-Gly-Asp-directed receptor on the surface of human melanoma cells exists in an divalent cation-dependent functional complex with the disialoganglioside GD2. J Cell Biol (1987) 1.44
Patient noncompliance: a major cause of late graft failure in cyclosporine-treated renal transplants. Transplant Proc (1988) 1.44
Ranitidine, cimetidine, and the cyclosporine-treated recipient. Transplantation (1986) 1.44
Enhancement of antibody-dependent cytotoxicity with a chimeric anti-GD2 antibody. J Immunol (1990) 1.44
A phase I study of neuroblastoma with the anti-ganglioside GD2 antibody 14.G2a. Cancer Immunol Immunother (1992) 1.44
Pharmacokinetics of sirolimus in stable renal transplant patients after multiple oral dose administration. J Clin Pharmacol (1997) 1.43
Production and characterization of monoclonal antibody to a melanoma specific glycoprotein. Hybridoma (1981) 1.42
Population pharmacokinetics and exposure-response relationships for basiliximab in kidney transplantation. The U.S. Simulect Renal Transplant Study Group. Transplantation (1999) 1.42
HLA matching assessed from early graft function. Transplant Proc (1987) 1.40
Biochemical changes in phytohemagglutinin stimulated human lymphocytes. Exp Cell Res (1966) 1.39
Localization of the gangliosides GD2 and GD3 in adhesion plaques and on the surface of human melanoma cells. Proc Natl Acad Sci U S A (1984) 1.39
O-acetylation of disialoganglioside GD3 by human melanoma cells creates a unique antigenic determinant. Science (1984) 1.38
Results of the double-blind, randomized, multicenter, phase III clinical trial of Thymoglobulin versus Atgam in the treatment of acute graft rejection episodes after renal transplantation. Transplantation (1998) 1.36
Effect of tissue inhibitor of the matrix metalloproteinases-2 expression on the growth and spontaneous metastasis of a human melanoma cell line. Cancer Res (1994) 1.36
Clinical pharmacokinetics of sirolimus. Clin Pharmacokinet (2001) 1.36
Alterations in rat pulmonary macrophage function by the immunosuppressive agents cyclosporine, azathioprine, and prednisolone. Transplantation (1983) 1.35
Remodeling of collagen matrix by human tumor cells requires activation and cell surface association of matrix metalloproteinase-2. Cancer Res (1998) 1.33
Isolation and characterization of a mitogen from pokeweek (Phytolacca americana). Proc Natl Acad Sci U S A (1967) 1.32
Matrix metalloproteinase-2 activation modulates glioma cell migration. J Cell Sci (1997) 1.31
A monoclonal antibody recognizes an O-acylated sialic acid in a human melanoma-associated ganglioside. J Biol Chem (1984) 1.31
Immunopharmacological monitoring of cyclosporin A-treated recipients of cadaveric kidney allografts. Transplantation (1982) 1.28
Proteases and protease inhibitors in tumor progression. Adv Exp Med Biol (1997) 1.27
Phase IB trial of chimeric antidisialoganglioside antibody plus interleukin 2 for melanoma patients. Clin Cancer Res (1997) 1.27
Targeting of lymphotoxin-alpha to the tumor elicits an efficient immune response associated with induction of peripheral lymphoid-like tissue. Immunity (2001) 1.26
KSA antigen Ep-CAM mediates cell-cell adhesion of pancreatic epithelial cells: morphoregulatory roles in pancreatic islet development. J Cell Biol (1998) 1.26
The impact of HLA mismatches on the survival of first cadaveric kidney transplants. N Engl J Med (1994) 1.26
Binding of cyclosporine by human lymphocytes and phospholipid vesicles. J Immunol (1983) 1.26
Molecular cloning of a human melanoma-associated chondroitin sulfate proteoglycan. Proc Natl Acad Sci U S A (1996) 1.25
De novo hemolytic uremic syndrome in renal transplant recipients immunosuppressed with cyclosporine. Surgery (1985) 1.24
Partial artificial heart (ALVAD) use with subsequent cardiac and renal allografting in a patient with stone heart syndrome. Artif Organs (1978) 1.23
Impact of rituximab therapy for treatment of acute humoral rejection. Clin Transplant (2009) 1.22
Elimination of established murine colon carcinoma metastases by antibody-interleukin 2 fusion protein therapy. Cancer Res (1997) 1.22
Biosynthetic studies of proteoglycans in human melanoma cells with a monoclonal antibody to a core glycoprotein of chondroitin sulfate proteoglycans. J Biol Chem (1984) 1.22
Correlation of chondroitin sulfate proteoglycan expression on proliferating brain capillary endothelial cells with the malignant phenotype of astroglial cells. Cancer Res (1991) 1.22
Tumor cell invasion through matrigel is regulated by activated matrix metalloproteinase-2. Anticancer Res (1998) 1.21
Variations at the carboxyl-terminal amino acid sequence of rabbit light chains with b4, b5 and b6 allotypic specificities. J Mol Biol (1969) 1.21
Evaluation of C3 receptors on lymphoid cells with different complement sources. J Immunol (1974) 1.19
Biological and chemical characterization of human histocompatibility antigens. Fed Proc (1971) 1.19
Transplantaton antigens. Science (1969) 1.18
Sirolimus-induced thrombocytopenia and leukopenia in renal transplant recipients: risk factors, incidence, progression, and management. Transplantation (2000) 1.18
A mechanism for neutrophil-mediated lysis of human neuroblastoma cells. Cancer Res (1993) 1.18
T cell-mediated eradication of murine metastatic melanoma induced by targeted interleukin 2 therapy. J Exp Med (1996) 1.17
Pharmacokinetic interactions augment toxicities of sirolimus/cyclosporine combinations. J Am Soc Nephrol (2001) 1.17
An autologous oral DNA vaccine protects against murine melanoma. Proc Natl Acad Sci U S A (2000) 1.17
The role of proto-oncogene Fra-1 in remodeling the tumor microenvironment in support of breast tumor cell invasion and progression. Oncogene (2009) 1.17
IFN-gamma-inducible protein-10 is essential for the generation of a protective tumor-specific CD8 T cell response induced by single-chain IL-12 gene therapy. J Immunol (2001) 1.16
The lymphocytotoxic reaction: the mechanism of rabbit complement action. J Immunol (1971) 1.15
Human tumor antigens. Adv Immunol (1987) 1.14
Immunosuppressive agents in organ transplantation: past, present, and future. Semin Nephrol (2000) 1.14
Suppression of spontaneous melanoma metastasis in scid mice with an antibody to the epidermal growth factor receptor. Cancer Res (1991) 1.13
Hepatobiliary and pancreatic complications of cyclosporine therapy in 466 renal transplant recipients. Transplantation (1987) 1.13
Monoclonal antibody and an antibody-toxin conjugate to a cell surface proteoglycan of melanoma cells suppress in vivo tumor growth. Proc Natl Acad Sci U S A (1983) 1.12
Expression of HL-A antigens in synchronized cultures of human lymphocytes. J Immunol (1972) 1.12
Possible contribution of pretransplant immune responder status to renal allograft survival differences of black versus white recipients. Transplantation (1991) 1.12
Eradication of human hepatic and pulmonary melanoma metastases in SCID mice by antibody-interleukin 2 fusion proteins. Proc Natl Acad Sci U S A (1996) 1.11